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We have observed that recanalization of thrombus
is related to neovascularization. This finding is novel
because the previous concepts of recanalization and
organization of the clot were primarily related to clot
retraction. In previous unpublished observations from
our laboratory, thrombus produced in a primate
model of inferior vena caval (IVC) ligation, either 13
days old or 90 days old, revealed a large number of
vascular channels that had positive results for staining
for the endothelial marker von Willebrand’s factor
and that contained significant quantities of the CXC
chemokine interleukin-8 (IL-8). These vascular chan-
nels developed in spite of the permanent ligature and
progressed over time. The CXC chemokine family
contains members that are either potent inducers or
inhibitors of angiogenesis, depending on the presence
or absence of glutamic acid, leucine, and arginine
(ELR motif) that precedes the first cysteine amino
acid residue of these chemokines. The members of the
CXC chemokine family that contain the ELR motif
are potent inducers of angiogenesis.1 IL-8 is an angio-
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Purpose: Thrombus organization after venous thromboembolism leading to recanaliza-
tion occurs at a variable rate. The angiogenic chemokine interleukin-8 (IL-8) has been
found in thrombus months after thrombus initiation. We hypothesize that thrombus
organization involves neovascularization and leukocyte influx and that IL-8 adminis-
tered at thrombus induction will promote thrombus organization.
Methods: A group of rats underwent inferior vena caval occlusive thrombosis. At throm-
bus induction and every 24 hours, the rats were administered IL-8 (1 m g) or serum albu-
min. The rats were killed at either day 4, day 8, or day 12, and, at death, colloidal car-
bon was perfused via the heart. The inferior vena cava was isolated, measured, weighed,
and formalin fixed. The sections were stained with anti-polymorphonuclear leukocyte
antibody, the endothelial marker factor VIII–related antigen, and with hematoxylin and
eosin. Thrombus neovascularization (colloidal carbon) with morphometric analysis was
normalized to the total thrombus area. In addition, the rats underwent perfusion with
fluorescein isothiocyanate dextran (molecular weight, 150,000) at death to correlate
with colloidal carbon perfusion, and thrombus fluorescence was determined.
Results: Thrombus cellularity initially involved neutrophils, followed by monocytes.
Significantly more neutrophils, monocytes, and cells that were defined as spindle shaped
(fibroblasts and endothelial cells) were noted in the animals treated with IL-8.
Neovascularization was significantly increased at day 4 in the animals treated with IL-8
versus the animals treated with serum albumin and was corroborated with a significant
increase in thrombus fluorescein isothiocyanate dextran fluorescence at day 4 in the rats
treated with IL-8. Colloidal carbon perfusion was noted within vascular channels with-
out extravasation and colocalized with factor VIII–related antigen.
Conclusion: This study shows that thrombus organization involves neovascularization
and that IL-8 augments thrombus organization. (J Vasc Surg 1999;30:885-93.)
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genic member of the CXC chemokine family.2 In this
study, we demonstrate that the administration of IL-
8 intravenously daily markedly promoted early neo-
vascularization of thrombus with a rat model of IVC
thrombosis and promoted leukocyte influx, these
processes together defining organization.
BACKGROUND AND CLINICAL 
RELEVANCE
The rat model of IVC ligation leading to a stasis-
induced venous thrombosis is applicable to the clin-
ical situation of venous thrombosis. First, we have
noted in this model the development of prograde
flow over time despite the proximal ligature, likely as
the result of side branches that are either too small
to ligate initially or that develop over time. We have
found prograde flow with ultrasound scanning by
day 4 after ligation. Because most patients with
venous thrombosis have prograde flow develop over
time, the rat model is applicable to the clinical con-
dition of venous thrombosis. Second, the model
previously has been used successfully to assess the
effect of thrombus on the vein wall.3,4 Thus, the
ability to study the thrombus itself should be appro-
priate in this model.
The potential importance of neovascularization is
found in the natural history of “adequately” treated
deep venous thrombosis. Extension or rethrombosis in
the first 9 to 12 months of the follow-up period occurs
in as many as 30% of the cases.5 If anticoagulation
therapy is adequate less than 25% of the time, there is
an even higher rate of extension or rethrombosis
(45%). Deep venous thrombosis and pulmonary
embolism remain significant clinical problems, affect-
ing approximately 200,000 to 300,000 patients per
year, and the incidence has changed little during the
past 30 years.6-8 It has been shown that the more com-
plete the clot resolution, the less the incidence of
severe symptoms of chronic venous insufficiency.9,10
Earlier recanalization or retraction of thrombi should
allow for a faster resolution of symptoms, such as pain,
swelling, and discomfort, and perhaps even lead to
improved vein valve preservation and decrease the inci-
dence of chronic venous insufficiency. Furthermore,
because clot occurrence and resolution are primarily
inflammatory responses,3 faster resolution may limit
the vein wall damage that contributes to venous insuf-
ficiency. Even if valvular incompetence is not prevent-
ed with augmented thrombus organization, reflux is
much more successfully treated than a combination of
reflux plus outflow obstruction as the result of a lack
of thrombus recanalization.
METHODS
Animal model. A group of rats (n = 100) was
subjected to IVC thrombosis with a previously
described model in which the IVC was permanently
ligated just below the level of the renal veins along
with ligature of large draining side branches (usually
two or three).3,4 Small branches remain, however, and
may serve as potential outflow channels as the throm-
bus organizes. At the time of thrombus induction and
then every 24 hours, the animals were administered
0.1 mL IL-8 (10 m g/mL in normal saline solu-
tion/0.1% serum albumin [SA]; 1 m g, R&D Systems,
Minneapolis, Minn) or an equal volume of the normal
saline solution/0.1% SA (Michigan Department of
Public Health, Lansing, Mich) as control.
Colloidal carbon. In initial studies, the rats (n =
60) were killed at either day 4, day 8, or day 12 and
were administered either SA or IL-8 (n = 10 each
group). At the time of death, colloidal carbon (5 mL)
was perfused via the beating left ventricle. The IVC
was isolated, removed, measured, weighed, and for-
malin fixed. The animal’s heart would typically contin-
ue beating for approximately 30 seconds after the IVC
was harvested. The IVC was divided into three seg-
ments (proximal, middle, and distal) and stained. The
staining included anti-neutrophil antibody (Accurate
Chemical, Westburg, NY), the endothelial marker fac-
tor VIII–related antigen (Dako, Denmark), and hema-
toxylin and eosin. For the immunohistochemical stain-
ing, a negative, immunoglobulin G, isotype-matched
control section was prepared next to the stained sec-
tion on every slide. A section from each segment was
assessed, and the section with the most colloidal car-
bon was analyzed. With an image analysis system
(Scion Corporation, Frederick, Md), thrombus neo-
vascularization as indicated by the presence of colloidal
carbon was normalized to total thrombus area and
presented as a percentage. This was performed with
the measurement of the area of blackness in the entire
thrombus (not including the blackness between the
edge of clot and the vein wall) and then indexed to
the area of the entire thrombus. Morphometrics of the
thrombus were evaluated in the same section in three
high-power fields for the presence of neutrophils,
monocytes, and spindle-shaped cells, and the cells
were counted.
Fluorescein isothiocyanate dextran. In the sec-
ond portion of this study, with another quantitative
technique, the rats (n = 40) were killed at either day 
4 or day 12. At the time of death, a 3-mL dose of flu-
orescein isothiocyanate (FITC) dextran (average
molecular weight [mw], 150,000; Sigma Chemical, St
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Louis, Mo) was injected into the tail vein. The use of
FITC dextran at mw 150,000 has been found in our
laboratory to remain confined to channels as com-
pared with lower mw molecules, which diffuse out of
channels into the thrombus. One hour later, the rats
were killed and the IVC was isolated, removed, mea-
sured, weighed, and divided into two segments. In
one segment, the clot was removed and placed into
phosphate-buffered saline solution (PBS). The clot
remained covered with foil in PBS for 24 hours at 4°C.
Then, the clot was homogenized for 30 seconds and
30% H2O2 (Sigma Chemical) and PBS were added in
a volume to normalize for removed clot weight and
length. After centrifugation at 1000 rpm at 4°C for 
10 minutes to remove bubbles, the sample was pipet-
ted into 96 well plates (Perkin Elmer, Norwolk,
Conn). The plates then were read on a fluorimeter
(Luminescence Spectrometer, Perkin Elmer) and
expressed in relative fluorescence units (FU). The sec-
ond segment was formalin fixed and placed into
parafin blocks and cut into slides for the visual assess-
ment of fluorescein by means of fluorescent micro-
scopy (Olympus BH2, Tokyo, Japan). The slides were
quantitated in a blinded fashion by one observer from
0 to 3+, on the basis of an arbitrary assessment of the
amount of fluorescence in the thrombus, and the
groups then were compared.
Statistical evaluation and animal use. Statistical
analysis included the mean ± the standard error of the
mean and the unpaired Student t tests for parametric
data and the Mann-Whitney test for nonparametric
data. Each experimental day was considered as an
independent event and not as a continuum of treat-
ment. Significance was defined as P less than .05. All
the rats were housed and cared for in the University
of Michigan Unit for Laboratory Animal Medicine
under the direction of a veterinarian according to the
“Principles of Laboratory Animal Care” (formulated
by the National Society for Medical Research) and the
Guide for the Care and Use of Laboratory Animals
(NIH Publication No. 86-23, revised 1985). The
protocol was approved by the University of Michigan
Committee on the Use and Care of Animals
(UCUCA #6574-6640A).
RESULTS
Thrombus morphometric analysis of leuko-
cytes and colloidal carbon perfusion. The pre-
dominate leukocytes in the thrombus at day 4 were
neutrophils, followed by monocytes at days 8 and
12. The presence of spindle-shaped cells (fibroblasts
and endothelial cells) rose consistently throughout
the course of the experimental period (Fig 1). At day
4, significantly more neutrophils were noted in the
thrombus in animals that had undergone treatment
with IL-8 than with SA (18 ± 2 vs 11 ± 1; P = .003;
Fig 2). At day 8, the predominance of neutrophils in
the animals that had undergone treatment with IL-
8 had reversed. At days 4 and 8, significantly more
monocytes were noted in the thrombus in those ani-
mals that were treated with IL-8 than in those that
were treated with SA (at 4 days, 15 ± 5 vs 5 ± 1, P
= .002; at 8 days, 44 ± 7 vs 20 ± 5, P = .030). At day
12, there were no differences between the groups in
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Fig 1. Morphometrics in thrombus. Number of cells in
three high-power fields per animal. A, Neutrophils; B,
monocytes; C, spindle-shaped cells.
the presence of either neutrophils (P = .36) or
monocytes (P = .64) in the thrombus. Spindle-
shaped cells were statistically more prominent in the
animals treated with IL-8 than in those treated with
SA at both day 4 (P = .049) and day 8 (P = .002).
At day 12, there was a trend of increased spindle-
shaped cells in the IL-8–treated group as compared
with the SA-treated group (P = .24; Fig 1).
Colloidal carbon perfusion was noted within the
vascular compartment without extravasation at all of
the time points (Figs 3 and 4) in association with
neovasculature co-localized with factor VIII–related
antigen (Fig 4). Most channels were found to be
lined with cells that appeared to be endothelial cells
and stained with factor VIII–related antigen,
although this was only a qualitative observation.
Significantly more colloidal carbon was measured in
those animals that were treated with IL-8 at day 4
than in those animals that were treated with SA
(0.41% ± 0.13% vs 0.11% ± 0.02%; P = .045). There
was no difference between the groups at day 8 (P =
.35) or at day 12 (P = .97), although there was a
trend of higher colloidal carbon perfusion in the ani-
mals treated with IL-8 at day 12.
Thrombus mass indexed to IVC length was not
different between the groups at either day 4 (IL-8,
0.065 ± 0.005; SA, 0.067 ± 0.005; P = .79), day 8
(IL-8, 0.063 ± 0.007; SA, 0.006 ± 0.006; P = .76),
or day 12 (IL-8, 0.039 ± 0.003; SA, 0.037 ± 0.003;
P = .64). Because inflammation augments thrombo-
sis and IL-8 may potentiate inflammation, the lack of
a difference in this measure between the groups sug-
gests that the infused IL-8 did not result in a signifi-
cant deleterious inflammatory thrombotic response.
Thrombus fluorescence. Thrombus fluores-
cence results revealed a statistically significant differ-
ence between the groups at the day 4 time point
(Fig 3). A 57% increase at this time was found in the
rats that were treated with IL-8 as compared with
the rats that were treated with SA (422 ± 54 FU vs
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Fig 2. Note decrease in stained neutrophils (black arrows) in middle of thrombus in animal
treated with serum albumin at day 4 (A) compared with increase in animal treated with inter-
leukin-8 at day 4 (B). In areas filled with colloidal carbon, again note decrease in stained neu-
trophils and also monocytes (white arrows) in animal treated with serum albumin at day 4 (C)
compared with increase in animal treated with interleukin-8 at day 4 (D). Anti-neutrophil anti-
body staining, all 1000· .
268 ± 45 FU; P = .041). At day 12, a 14% increase
trend was noted in the rats treated with IL-8 as com-
pared with the control rats treated with SA (122 ±
25 FU vs 107 ± 14 FU; P = .61) that did not reach
statistical significance. Microscopic inspection of the
fluorescence of the thrombus sections at day 4
revealed significantly more fluorescence in the ani-
mals treated with IL-8 (median score, 3.0; 25% to
75% quartiles, 2.5 to 3.0) than in the control rats
treated with SA (median score, 1.0; 25% to 75%
quartiles, 1.0 to 2.0; P = .008; Fig 5) and nicely cor-
roborated the colloidal carbon perfusion data.
DISCUSSION
Angiogenesis is the growth of new capillary blood
vessels (neovascularization) and is an essential biolog-
ic process.11-15 Normally, angiogenesis occurs infre-
quently in adults. Yet, angiogenesis may be rapidly
induced in response to a number of diverse physio-
logic stimuli, wound healing being among the most
extensively studied.16 Angiogenesis associated with
wound healing is tightly controlled in a temporal
manner. Normally, the rate of capillary endothelial cell
turnover in adult mammalian organisms can be mea-
sured in months or years.17,18 However, when quies-
cent endothelial cells lining venules are stimulated,
they degrade their basement membrane and proximal
extracellular matrix, migrate directionally, divide, and
organize into new functional capillaries invested by a
basal lamina, all within a matter of days. The two
important aspects of this process are: new capillary
blood vessel formation is rapid and controlled, and it
is transient and characterized by regression. The fac-
tors that contribute to thrombus recanalization are
presently unknown. The concept of thrombus recana-
lization has not previously been related to neovascu-
larization for venous thrombosis.
The CXC chemokine family of cytokines contains
members that are either potent angiogenic or angio-
static factors. The determination of whether these
chemokines behave in the promotion of new vessel
formation depends on the presence or the absence of
glutamic acid, leucine, and arginine (ELR motif) that
precedes the first cysteine amino acid residue of the
primary structure of these molecules. The members
that contain the ELR motif are angiogenic. IL-8 is a
member of the CXC chemokine family that contains
the ELR motif, and it is a potent angiogenic fac-
tor.2,19,20 Other CXC angiogenic factors include
epithelial neutrophil-activating protein-78 (ENA-78),
growth-related oncogene (GRO- a , GRO- b , and
GRO-g ), granulocyte chemotactic protein-2 (GPC-2),
and platelet basic protein and its NH2-truncated forms
(connective tissue activating protein-III, beta-throm-
boglobulin, and neutrophil-activating protein-2). The
CXC chemokines that lack the ELR motif include
platelet factor 4 (PF-4), interferon gamma-inducible
protein 10 (IP-10), and monokine induced by gamma
interferon (MIG). All of these angiogenic and angio-
static molecules function independent of their role as
mediators of leukocyte chemoattractants.21
Recombinant IL-8 mediates both endothelial cell
chemotactic and proliferative activity in vitro and
angiogenic activity in vivo. Endothelial cell chemo-
taxis, proliferation, and angiogenesis occur in
response to recombinant IL-8 in the corneal micro-
pocket model. The concentration of IL-8 that func-
tions in angiogenesis, 10 nmol/L, compares well with
the amount reported for the induction of corneal
angiogenic activity by factors such as tumor necrosis
factor– a ( TNF- a) , a –fibroblast growth factor ( a -
FGF), b –fibroblast growth factor ( b –FGF), angio-
genin, angiotropin, and vascular-derived endothelial
growth factor (VEGF).2 The importance of the pres-
ence of neutrophils in the thrombus at the early, day
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Fig 3. Neovascularization at days 4 and 12 represented
with colloidal carbon (A) and thrombus fluorescence (B).
Statistical significance noted at day 4 (P < .05).
4 time point remains to be determined, and studies of
neutrophil depletion to answer this question are
planned. Monocytes/macrophages represent a major
source of angiogenic wound activity, and they make
up a significant contribution of the cellular activity of
the thrombus. Monocytes may direct neovasculariza-
tion by directly releasing factors that upregulate cell
adhesion molecules essential for new vessel forma-
tion.22 Monocytes also synthesize tissue plasminogen
activator, urokinase, and the urokinase receptor, fac-
tors that likely participate in the process of thrombus
resolution.23 Importantly, because IL-8 does not
recruit monocytes, the monocyte increase at days 8
and 12 reflects thrombus organization and not mere-
ly inflammatory cell recruitment.
Acute thrombosis is associated with rapid coagu-
lation and the generation of a fibrin-dominated
matrix and the release of platelet-derived cytokines.
Initially, the platelets involved in the thrombus favor
angiostatic chemokines, such as PF-4. However, as
the thrombus ages during the first 24 to 72 hours,
there is a transition toward a more cellular phase of
inflammation and the balance shifts in favor of
chemokines involved in neutrophil and monocyte
chemotaxis, including IL-8. Along with inflammato-
ry cell emigration and thrombolysis of the clot, neo-
vascularization is promoted. In this study, we found
that systemically administered IL-8 accelerated
thrombus neovascularization, as shown both by the
injection of colloidal carbon at the time of death and
by the use of FITC-labeled dextran. Thrombus cel-
lularity was also modified with IL-8 treatment, with
greater numbers of neutrophils, monocytes, and
spindle-shaped cells in the thrombus throughout the
experimental period. These cells were especially
prominent in areas in juxtaposition to neovessels.
We hypothesized that the administered IL-8 is taken
up by the Duffy antigen on the red blood cells and
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Fig 4. Colloidal carbon in thrombus, present in channels cut in transverse orientation at day
12 in animal treated with interleukin-8. A, 40· ; B, 100· . Note that colloidal carbon is only
present in channels lined by cells with characteristics of endothelium and not in other areas of
thrombus. Note also predominance of monocytic infiltrate in areas of channels. C, Factor
VIII–related antigen staining at day 12 in animal treated with interleukin-8 co-localized to cells
lining channels (arrow) sectioned in transverse orientation that contain colloidal carbon.
1000 · , positive staining; D, 1000 · , negative staining with immunoglobulin G isotype-
matched control. All hematoxylin and eosin staining.
would thus be concentrated in the thrombus.
Although not quantitated in this study, we have
noted by means of immunohistochemical staining
that IL-8 staining is found associated with the red
blood cells in the thrombus. The statistically signifi-
cant increase in colloidal carbon and thrombus fluo-
rescence that was noted with IL-8 at day 4 was not
found at days 8 or 12 for colloidal carbon or at day
12 for thrombus fluorescence, although the trends
remained for colloidal carbon. This is likely because
once the thrombus forms, no additional IL-8 can
reach the red blood cells and the maximum stimulus
for new vessel formation has already been attained
within the thrombus. Future studies will address this
issue with the infusion of IL-8 only at the beginning
of the experimental period, not daily.
Our results confirm the ability of IL-8 to
enhance neovascularization by shifting the throm-
bus organization to an earlier time point. The data
also suggest that angiogenic CXC chemokines, such
as IL-8, could be used in the treatment of venous
thrombosis to potentially augment early recanaliza-
tion and re-establish perfusion, especially if infused
selectively into the thrombus. However, the poten-
tial deleterious effects of IL-8 infusion regarding
vein wall inflammation will need to be evaluated.
Alternatively, IL-8–stimulated neovascularization
may be more important early for promoting inflam-
matory cell influx into the thrombus and later for
clot retraction. This may be why lesser channels
over time were noted with colloidal carbon and
thrombus fluorescence.
SUMMARY
In summary, we have demonstrated neovascular-
ization in organizing thrombi. In addition, the
angiogenic CXC chemokine IL-8 has been shown to
promote thrombus organization by increasing early
neovascularization and promoting inflammatory cell
influx. Future studies will address the ability of other
angiogenic and angiostatic CXC chemokines to
either augment or lessen the process of neovascular-
ization. In addition, the functional importance of
neovascularization will need to be determined, as to
its ability to improve flow through the thrombus
and thus decrease venous hypertension. These find-
ings, if confirmed, suggest that factors, such as IL-8,
could be used in the treatment of venous thrombo-
sis to promote organization of the thrombus.
We thank Gerald D. Abrams, MD, Department of
Pathology, for his contributions.
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Dr E. John Harris, Jr (Stanford, Calif). Dr Wakefield
and colleagues have presented more of their work on the
integration of thrombosis and inflammation in venous
thrombosis. In this study, the group used a rat model of
venous thrombosis that involved ligation of the inferior
vena cava and its tributaries. At thrombus induction and
then every 24 hours until death, the animals received a
systemic dose of interleukin-8 or serum albumin as a con-
trol. Interleukin-8 is a soluble chemokine that is believed
to be active in the process of angiogenesis. The animals
were killed at 4, 8, and 12 days. Two groups of animals
then were established, with one group receiving systemic
colloidal carbon before death and the other receiving 
systemic FITC dextran before death. Thrombus was
weighed in each animal and normalized against caval
length. Neovascularization was assessed with the amount
of colloidal carbon uptake indexed to the total thrombus
area. Thrombus morphometrics were analyzed with usual
staining, with the addition of specific staining for neu-
trophils and endothelial cells. Thrombus cellularity exhib-
ited predominantly neutrophils at 4 days but then 
predominantly monocytes at 8 and 12 days, with spindle-
shape cells rising steadily throughout the phase of their
study. Animals treated with interleukin-8 had an earlier
peak in the neutrophil and monocyte levels than did ani-
mals treated with serum albumin. Yet, by 12 days, there
was no significant difference between animals treated
with IL-8 and serum albumin controls. Colloidal carbon
was only identified in the channels that stained positively
for endothelial cell markers. Animals treated with inter-
leukin-8 had maximal colloidal uptake at 4 days, and by 8
days, animals treated with serum albumin had reached
this same level. By 12 days, colloidal carbon was similar
between the animals treated with IL-8 and the animals
treated with serum albumin.
The authors conclude that thrombus organization
involves angiogenesis. I agree with this statement because
we have also identified neovascularization in our model of
venous thrombosis. The authors conclude that inter-
leukin-8 augments thrombus neovascularization and orga-
nization, and this may also be true. Yet, on the basis of the
data presented, I am less convinced. This leads me to sev-
eral questions for Dr Wakefield.
In the well-written manuscript provided to me, the
authors suggest that IL-8 is taken up by the Duffy antigen
on red blood cells and thus concentrated in the thrombus.
How then does systemically injected interleukin-8 enter
the formed vena caval thrombus after time zero? As you
know, systemically infused lytic agents fail to gain access to
an obstructing venous thrombus because these agents go
with the flow, which is always away from the obstruction.
I suspect that the interleukin-8 systemically administered
is similarly following the flow away from your thrombus. I
wonder whether the interleukin-8 effects that you observe
on cellularity and neovascularity are not those that are
introduced at time zero, and I wonder whether a titration
DISCUSSION
curve of interleukin-8 at time zero would not have been a
better test. Have you thought of leaving a catheter in the
vena cava so administration of interleukin-8 can gain
access to the thrombus? Have you tried to stain the
thrombus for the presence of interleukin-8? Can you
quantify the amount of interleukin-8 in the thrombus to
show that systemic infusion does indeed augment throm-
bus levels? We do not learn from the presentation or the
manuscript whether the thrombus in this model ever does
organize or recanalize. Have these animals been followed
to 4 weeks or at least until recanalization is identified? In
our model of thrombosis in the rat, thrombosed segments
do recanalize, even in the presence of persistent outflow
obstruction. Do the authors believe that the animals treat-
ed with interleukin-8 will recanalize sooner than those
treated with the control, serum albumin? Finally, have the
authors considered developing a similar thrombosis model
in the mouse where transgenic and knock-out technolo-
gies could be used to form an IL-8 knock-out or trans-
genic animal and perhaps some of these questions could
be answered.
I enjoyed this presentation and the manuscript, and I
look forward to the further development of this exciting
work from this productive group at Michigan. I thank the
American Venous Forum for the opportunity to discuss
this work.
Dr Thomas W. Wakefield. Thank you. Yes, I agree. I
think probably it is IL-8 that is given just before the throm-
bus forms that is important, and we would like to repeat the
studies with just giving IL-8 at the beginning and not giv-
ing it daily. My speculation would be that we would see the
exact same results. In answer to your question about
whether or not we have considered leaving a catheter in the
inferior vena cava so that IL-8 can gain direct access to the
thrombus, we believe because IL-8 is taken up by the Duffy
antigen on red blood cells that the IL-8 is already present in
the thrombus at the time that the thrombus forms. We have
stained the thrombus for the presence of IL-8, and we have
noted that there is visible staining on the red blood cells that
can be noted. Although we did not perform quantitation of
IL-8 levels in the thrombus in the current study, we have
noted high levels of IL-8 in primate thrombus from 2 weeks
to 3 months of age, and in fact, this is the genesis for the
current investigative efforts. We do not know with pro-
longed experiments whether or not the animals given IL-8
would recanalize sooner than those not given IL-8, and
these experiments are planned. Finally, concerning whether
or not we have considered developing similar thrombosis
models in the mouse where transgenic and knock-out tech-
nologies could be used, we have developed a similar model
in the mouse and can produce venous thrombosis with sim-
ple ligation of the inferior vena cava. However, we have not
yet performed the same studies as reported in the present
experiment in the mouse model.
I would like to thank you for your questions and for
your discussion and would like to thank the American
Venous Forum for the opportunity to present and discuss
our work.
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